Ezetimibe/rosuvastatin - MSD - to be deleted

Drug Profile

Ezetimibe/rosuvastatin - MSD - to be deleted

Latest Information Update: 23 Jun 2016

Price : $50

At a glance

  • Originator Merck Sharp & Dohme
  • Class Antihyperlipidaemics; Azetidines; Fluorobenzenes; Propanols; Pyrimidines; Small molecules; Sulfonamides
  • Mechanism of Action Cholesterol absorption inhibitors; HMG-CoA reductase inhibitors; NPC1L1 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase III Hypercholesterolaemia

Most Recent Events

  • 01 Jun 2016 Merck Sharp & Dohme initiates a phase III trial for Hypercholesterolaemia in Japan (NCT02741245)
  • 01 May 2016 Phase-III clinical trials in Hypercholesterolaemia in Japan (PO) (NCT02748057)
  • 20 Apr 2016 Merck Sharp & Dohme plans a phase III trial for Hypercholesterolaemia in Japan (PO) (NCT02748057)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top